Immutep reaches key milestone in autoimmune disease study
Immutep (ASX:IMM), a pioneer in LAG-3 immunotherapy, has reached a milestone in the treatment of autoimmune diseases.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Immutep (ASX:IMM), a pioneer in LAG-3 immunotherapy, has reached a milestone in the treatment of autoimmune diseases.
Racura Oncology (ASX:RAC) announced the dosing of the third patient in its CPACS Phase 1 clinical trial.
Nexalis Therapeutics (ASX:NX1) has commenced dosing in its Phase 1 clinical trial of IRX-616a.
Firebrick Pharma (ASX:FRE) has secured a key patent in the Philippines for Nasodine.
Vitura Health (ASX:VIT) announced a binding commercial distribution agreement with MedReleaf Australia.
Firebrick Pharma (ASX:FRE) has appointed Nilesh Wadhwa as the new Head of Business Development and Licensing.
BlinkLab (ASX:BB1) has reached a critical regulatory milestone with the onboarding of the University of Arkansas as its tenth and final clinical site.
Dimerix (ASX:DXB) announced plans to conduct a blinded assessment of the statistical assumptions underpinning its ongoing ACTION3 study.
Telix Pharmaceuticals (ASX:TLX) has resubmitted its New Drug Application to the US Food and Drug Administration for TLX101-Px.
Australian biotech firm Racura Oncology (ASX:RAC) secured critical governance approval from Monash Health.
Global health-tech innovator Oneview Healthcare (ASX:ONE) secured $19 million through an upsized two-tranche placement.
InteliCare (ASX:ICR) has announced a five-year partnership with leading Victorian not-for-profit aged care provider, MECWA.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade